Loading

OBI Pharma, Inc.

June 04, 2024
Company Presentation
Oncology
Company Presentation Theater 2
OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC platform technologies and has a novel oncology portfolio: ADC platform technologies - GlycOBI™ - ThiOBI™ Novel cancer therapeutics - Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine) - OBI-833 (Globo H cancer vaccine) - OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme) - OBI-992 (TROP2 ADC, Cys-conjugation platform)) - OBI-902 (TROP2 ADC, GlycOBI platform) - OBI-904 (Nectin4 ADC, GlycOBI platform)
OBI Pharma, Inc.
Company Website: https://www.obipharma.com/
Lead Product in Development: Adagloxad simolenin
Number Of Unlicensed Products (For Which You Are Seeking Partners): 5

Exchange

Taipei Exchange

Ticker

4174.TWO

Company HQ City

Taipei City

Company HQ State

Taipei

Company HQ Country

Taiwan

CEO/Top Company Official

Heidi Wang, PhD

Development Phase of Primary Product

Phase III
Speakers
Teng-Yi Huang, PhD
Director, R&D Medicinal Chemistry
OBI Pharma, Inc.
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS